{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:24:19Z","timestamp":1772756659009,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T00:00:00Z","timestamp":1298419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T00:00:00Z","timestamp":1298419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1038\/npp.2011.14","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T14:58:32Z","timestamp":1298473112000},"page":"1289-1295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy"],"prefix":"10.1038","volume":"36","author":[{"given":"Joseph I","family":"Friedman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Bowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Parak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Iskander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D","family":"Tsopelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yann","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladan","family":"Novakovick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip D","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth L","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,23]]},"reference":[{"key":"BFnpp201114_CR1","unstructured":"American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Health Disorders (4th edn) Washington DC."},{"key":"BFnpp201114_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archpsyc.1992.01820080023004","volume":"49","author":"NC Andreasen","year":"1992","unstructured":"Andreasen NC, Flaum M, Arndt S (1992). The comprehensive assessment of symptoms and history (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 49: 615\u2013623.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201114_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4088\/JCP.v66n0109","volume":"66","author":"AE Anil Ya\u2202cio\u2202lu","year":"2005","unstructured":"Anil Ya\u2202cio\u2202lu AE, Kivircik Akdede BB, Turgut TI, T\u00fcm\u00fckl\u00fc M, Yazici MK, Alptekin K, Ertu\u01e7rul A, Jayathilake K, G\u00f6\u01e7\u00fc\u015f A, Tunca Z, Meltzer HY (2005). A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66: 63\u201372.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201114_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/ajp.151.1.20","volume":"151","author":"A Breier","year":"1994","unstructured":"Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter Jr WT (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20\u201326.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR5","first-page":"233","volume":"7","author":"G Chouinard","year":"1980","unstructured":"Chouinard G, Ross-Chouinard A, Annable L, Jones B (1980). The extrapyramidal symptom rating scale. Can J Neurol Sci 7: 233.","journal-title":"Can J Neurol Sci"},{"key":"BFnpp201114_CR6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1176\/ajp.154.9.1243","volume":"154","author":"RR Conley","year":"1997","unstructured":"Conley RR, Carpenter WT Jr, Tamminga CA (1997). Time to clozapine response in a standardized trial. Am J Psychiatry 154: 1243\u20131247.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0014-2999(76)90277-6","volume":"36","author":"I Creese","year":"1976","unstructured":"Creese I, Feinberg AP, Snyder SH (1976). Butyrphenone influence on the opiate receptor. Eur J Pharmacol 36: 231\u2013235.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp201114_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1017\/S1461145710000490","volume":"13","author":"WW Fleischhacker","year":"2010","unstructured":"Fleischhacker WW, Heikkinen ME, Oli\u00e9 JP, Landsberg W, Dewaele P, McQuade RD et al (2010). Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13: 1115\u20131125.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFnpp201114_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2006.12.030","volume":"92","author":"O Freudenreich","year":"2007","unstructured":"Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC (2007). Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 92: 90\u201394.","journal-title":"Schizophr Res"},{"key":"BFnpp201114_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0006-3223(97)00227-8","volume":"42","author":"J Friedman","year":"1997","unstructured":"Friedman J, Ault K, Powchik P (1997). Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 42: 522\u2013523.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201114_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02849987","volume":"24","author":"Y Gen\u00e7","year":"2007","unstructured":"Gen\u00e7 Y, Taner E, Candansayar S (2007). Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 24: 1\u201313.","journal-title":"Adv Ther"},{"key":"BFnpp201114_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2340\/00015555625558","volume":"62","author":"K Hamann","year":"1982","unstructured":"Hamann K, Avnstorp C (1982). Delusions of infestation treated by pimozide: a double-blind crossover clinical study. Acta Derm Venereol 62: 55\u201358.","journal-title":"Acta Derm Venereol"},{"key":"BFnpp201114_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00004714-199312000-00003","volume":"13","author":"M Hasegawa","year":"1993","unstructured":"Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY (1993). Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 13: 383\u2013390.","journal-title":"J Clin Psychopharmacol"},{"key":"BFnpp201114_CR14","volume-title":"Cardiology for the House Officer: Second Edition","author":"JW Heger","year":"1987","unstructured":"Heger JW, Niemann JT, Criley JM (1987). Cardiology for the House Officer: Second Edition Copyright 1987 Williams & Wilkins: Baltimore MD."},{"key":"BFnpp201114_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa053222","volume":"354","author":"WG Honer","year":"2006","unstructured":"Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A et al (2006). Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354: 472\u2013482.","journal-title":"N Engl J Med"},{"key":"BFnpp201114_CR16","first-page":"233","volume":"44","author":"GC Johnson","year":"1983","unstructured":"Johnson GC, Anton RF (1983). Pimozide in delusions of parasitosis. J Clin Psychiatry 44: 233.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201114_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","volume":"162","author":"RC Josiassen","year":"2005","unstructured":"Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW et al (2005). Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162: 130\u2013136.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789\u2013796.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201114_CR19","volume-title":"Positive and Negative Syndromes in Schizophrenia","author":"Kay","year":"1991","unstructured":"Kay (1991). Positive and Negative Syndromes in Schizophrenia. Brunner\/Mazel: New York."},{"key":"BFnpp201114_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1176\/ajp.152.2.179","volume":"152","author":"MH Kronig","year":"1995","unstructured":"Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T et al (1995). Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152: 179\u2013182.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR21","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","volume":"151","author":"JA Lieberman","year":"1994","unstructured":"Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A et al (1994). Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151: 1744\u20131752.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al, CATIE Investigators (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600\u2013610.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR23","first-page":"117","volume":"55","author":"DD Miller","year":"1994","unstructured":"Miller DD, Fleming F, Holman TL, Perry PJ (1994). Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 55: 117\u2013121.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201114_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/070674378503000813","volume":"30","author":"A Munro","year":"1985","unstructured":"Munro A, O\u2019Brien JV, Ross D (1985). Two cases of \u2018pure\u2019 or \u2018primary\u2019 erotomania successfully treated with pimozide. Can J Psychiatry 30: 619\u2013622.","journal-title":"Can J Psychiatry"},{"key":"BFnpp201114_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/BF02246112","volume":"117","author":"OV Olesen","year":"1995","unstructured":"Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C (1995). Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology (Berl) 117: 371\u2013378.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp201114_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0028-3908(77)90023-5","volume":"16","author":"SJ Peroutka","year":"1977","unstructured":"Peroutka SJ, U\u2032Prichard DC, Greenberg DA, Snyder SH (1977). Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology 16: 549\u2013556.","journal-title":"Neuropharmacology"},{"key":"BFnpp201114_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1176\/ajp.148.10.1406-b","volume":"148","author":"PJ Perry","year":"1991","unstructured":"Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148: 231\u2013235.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/archpsyc.1992.01820050009001","volume":"49","author":"D Pickar","year":"1992","unstructured":"Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992). Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345\u2013353.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp201114_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-197612010-00001","volume":"12","author":"RM Pinder","year":"1976","unstructured":"Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS (1976). Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 12: 1\u201340.","journal-title":"Drugs"},{"key":"BFnpp201114_CR30","first-page":"133","volume":"55","author":"SG Potkin","year":"1994","unstructured":"Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y et al (1994). Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55: 133\u2013136.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp201114_CR31","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1007\/BF00442568","volume":"99","author":"WZ Potter","year":"1989","unstructured":"Potter WZ, Ko GN, Zhang LD, Yan WW (1989). Clozapine in China: a review and preview of US\/PRC collaboration. Psychopharmacology (Berl) 99: S87\u2013S91.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp201114_CR32","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(75)92302-8","volume":"7921","author":"TM Reilly","year":"1975","unstructured":"Reilly TM (1975). Letter: pimozide in monosymptomatic psychosis. Lancet 7921: 1385\u20131386.","journal-title":"Lancet"},{"key":"BFnpp201114_CR33","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(75)91323-9","volume":"7903","author":"BE Riding","year":"1975","unstructured":"Riding BE, Munro A (1975). Letter: pimozide in monosymptomatic psychosis. Lancet 7903: 400\u2013401.","journal-title":"Lancet"},{"key":"BFnpp201114_CR34","first-page":"429","volume":"3","author":"RH Roth","year":"1994","unstructured":"Roth RH (1994). Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors. Commun Psychopharmacol 3: 429\u2013433.","journal-title":"Commun Psychopharmacol"},{"key":"BFnpp201114_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/swra\/19.3.9","volume":"6","author":"LC Schneider","year":"1983","unstructured":"Schneider LC, Streuening EL (1983). SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr 6: 9\u201321.","journal-title":"Soc Work Res Abstr"},{"key":"BFnpp201114_CR36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1176\/ajp.140.9.1183","volume":"140","author":"AK Shapiro","year":"1983","unstructured":"Shapiro AK, Shapiro E, Eisenkraft GJ (1983). Treatment of Gilles de la Tourette syndrome with pimozide. Am J Psychiatry 140: 1183\u20131186.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0924-9338(97)80205-2","volume":"12","author":"R Shiloh","year":"1997","unstructured":"Shiloh R, Zemishlany Z, Aizenberg D, Weizman A (1997). Sulpiride adjunction to clozapine in treatment-resistant schizophrenic patients: a preliminary case series study. Eur Psychiatry 12: 152\u2013155.","journal-title":"Eur Psychiatry"},{"key":"BFnpp201114_CR38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/0006-3223(86)90219-2","volume":"21","author":"LH Tecott","year":"1986","unstructured":"Tecott LH, Kwong LL, Uhr S, Peroutka S (1986). Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine and pimozide. Biol Psychiatry 21: 1114\u20131122.","journal-title":"Biol Psychiatry"},{"key":"BFnpp201114_CR39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","volume":"156","author":"K Wahlbeck","year":"1999","unstructured":"Wahlbeck K, Cheine M, Essali A, Adams C (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156: 990\u2013999.","journal-title":"Am J Psychiatry"},{"key":"BFnpp201114_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF00498834","volume":"296","author":"JR Walters","year":"1976","unstructured":"Walters JR, Roth RH (1976). Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol 296: 5\u201314.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"updated-by":[{"DOI":"10.1038\/npp.2011.46","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T00:00:00Z","timestamp":1302739200000}},{"DOI":"10.1038\/npp.2011.68","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T00:00:00Z","timestamp":1313452800000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp201114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp201114","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp201114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:06:52Z","timestamp":1712236012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp201114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,23]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["BFnpp201114"],"URL":"https:\/\/doi.org\/10.1038\/npp.2011.14","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,23]]},"assertion":[{"value":"19 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jean-Pierre Lindenmayer has received grant support from Johnson & Johnson, Eli Lilly and Company, Pfizer, AstraZeneca, Otsuka, and Dainippon-Sumitomo. Lindenmayer has served as a consultant to Eli Lilly, Johnson & Johnson, Merck, and Shire Pharmaceuticals. Frances Alcantara has received grant support from Johnson & Johnson, Eli Lilly and Company, Pfizer, AstraZeneca, Dainippon-Sumitomo, and Otsuka. Parak Mohan has received grant support from Johnson & Johnson, Eli Lilly and Company, Pfizer, AstraZeneca, Dainippon-Sumitomo, and Otsuka. Adel Iskander has received grant support from Johnson & Johnson, Eli Lilly and Company, Pfizer, AstraZeneca, Dainippon-Sumitomo, and Otsuka. David Adler has received speaker honoraria from Eli Lilly and Company. He is currently employed as a research psychiatrist by Neurobehavioral Research (Cedarhurst, NY). Philip D Harvey has served as a consultant for Eli Lilly and Company, Merck and Company, Shire Pharmaceuticals, Johnson & Johnson, and Dainippon-Sumitomo America. He has grant support from AstraZeneca. Kenneth L Davis's wife receives royalty income from Janssen Pharmaceuticals and Shire Pharmaceuticals from the sale of a patented drug for the treatment of Alzheimer's disease. The remaining authors report no financial relationships with commercial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}